Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Sep;22(6):876-881.
doi: 10.1111/pedi.13239. Epub 2021 Jun 10.

Identification of GCK-maturity-onset diabetes of the young in cases of neonatal hyperglycemia: A case series and review of clinical features

Affiliations
Case Reports

Identification of GCK-maturity-onset diabetes of the young in cases of neonatal hyperglycemia: A case series and review of clinical features

Alice E Hughes et al. Pediatr Diabetes. 2021 Sep.

Abstract

Heterozygous mutations in GCK result in a persistent, mildly raised glucose from birth, but it is usually diagnosed in adulthood as maturity-onset diabetes of the young (MODY), where hyperglycemia is often an incidental finding. The hyperglycemia of GCK-MODY is benign and does not require treatment, but is important to be aware of, particularly in females where it has implications for managing pregnancy. We present three cases of neonatal hyperglycemia resulting from a heterozygous mutation in GCK, illustrating its clinical presentation and evolution in early life. In summary, as with adults, neonatal hyperglycemia is an incidental finding, does not require treatment and has no adverse consequences for health. Neonates and their parents should be referred for genetic testing to confirm the diagnosis, avoid a label of diabetes and enable pregnancy counseling for females found to be affected.

Keywords: GCK-MODY; glucokinase; hyperglycemia; monogenic diabetes of the young; neonatal diabetes.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest disclosure:

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Partial pedigrees for cases of GCK-MODY diagnosed where hyperglycemia was first identified in the neonatal period. Filled symbols represent individuals with a genetic diagnosis of GCK-MODY, genotypes are provided under the symbols. The clinical diagnosis is provided under the symbols for individuals affected by diabetes (for the father of Case 1, the affected phenotype is assumed based on genotype). GDM = Gestational Diabetes Mellitus. T2D = Type 2 diabetes. An arrow points to the proband in each family.

References

    1. Chakera AJ, Steele AM, Gloyn AL, et al. Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation. Diabetes Care. 2015;38(7):1383–1392. doi: 10.2337/dc14-2769. - DOI - PubMed
    1. Gloyn AL. Glucokinase (GCK) mutations in hyper- and hypoglycemia: Maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Human Mutation. 2003;22(5):353–362. doi: 10.1002/humu.10277. - DOI - PubMed
    1. Steele AM, Wensley KJ, Ellard S, et al. Use of HbA1c in the Identification of Patients with Hyperglycaemia Caused by a Glucokinase Mutation: Observational Case Control Studies. PLoS One. 2013;8(6) doi: 10.1371/journal.pone.0065326. - DOI - PMC - PubMed
    1. Vionnet N, Stoffel M, Takeda J, et al. Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature. 1992;356(6371):721–722. doi: 10.1038/356721a0. - DOI - PubMed
    1. Sturis J, Kurland IJ, Byrne MM, et al. Compensation in pancreatic beta-cell function in subjects with glucokinase mutations. Diabetes. 1994;43(5):718–723. doi: 10.2337/diab.43.5.718. - DOI - PubMed

Publication types

Supplementary concepts